A combination of psoralen and ultraviolet-A (320-400 nm) (UVA) radiation, commonly referred to as """"""""PUVA"""""""", is being widely used in the treatment of psoriasis. With the wide-spread use of PUVA therapy, considerable attention has been focused on the mutagenic and carcinogenic effects of PUVA. Numerous studies have shown that PUVA treatment induces skin cancer in mice. In addition, several reports indicate that PUVA therapy is a risk factor for skin cancer development in humans. However, the molecular mechanisms that are involved in the pathogenesis of PUVA-induced skin cancers are poorly understood. The long-term goal of this proposal is to identify the genetic alterations that are associated with the origin and development of skin cancer in PUVA treated patients. Since the etiology of human skin cancers arising in psoriasis patients who have undergone PUVA therapy is controversial, it may be possible to use the p53 tumor suppressor gene as a molecular marker and determine whether these skin cancers are induced by UV radiation or by PUVA. Since UV and PUVA induces different types of DNA damage, we hypothesize that mutations induced by these two carcinogenic agents are also different, and thus may leave their unique """"""""signature"""""""".
Our specific aims are: (1) To identify ras and p53 mutations associated with PUVA-induced mouse skin cancers, (2) To determine whether PUVA-induced ras and p53 mutations are an early or a late event during PUVA carcinogenesis, and (3) To determine whether human skin cancers from psoriasis patients who have undergone PUVA therapy harbor ras and p53 mutations that are similar to those detected in PUVA- induced murine skin cancers. Mutations in ras and p53 genes will be identified by single strand conformation polymorphism analysis and nucleotide sequencing. A thorough clinical evaluation of patient's prior exposure to chemotherapy or radiotherapy, number, duration, and intensity of exposure to PUVA, skin type, etc., will be made to correlate ras and p53 mutation data with clinical data. ras and p53 mutation studies in PUVA, 4,4',6-trimethylangelicin+UVA and angelicin+UVA induced mouse skin tumors should provide important information on the role of monofunctional adducts and DNA cross-links in PUVA carcinogenesis. Information obtained from p53 studies in human skin cancers from PUVA-treated patients may provide clues to the etiology of these skin cancers, which may be useful for the future formulation of intervention protocols.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA067174-02
Application #
2008832
Study Section
General Medicine A Subcommittee 2 (GMA)
Project Start
1996-03-01
Project End
1999-12-31
Budget Start
1997-01-01
Budget End
1997-12-31
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Microbiology/Immun/Virology
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Santamaria, A B; Davis, D W; Nghiem, D X et al. (2002) p53 and Fas ligand are required for psoralen and UVA-induced apoptosis in mouse epidermal cells. Cell Death Differ 9:549-60
Stern, Robert S; Bolshakov, Svetlana; Nataraj, Arun J et al. (2002) p53 mutation in nonmelanoma skin cancers occurring in psoralen ultraviolet a-treated patients: evidence for heterogeneity and field cancerization. J Invest Dermatol 119:522-6
Kutach, L S; Bolshakov, S; Ananthaswamy, H N (1999) Detection of mutations and polymorphisms in the p53 tumor suppressor gene by single-strand conformation polymorphism analysis. Electrophoresis 20:1204-10
Nataraj, A J; Wolf, P; Cerroni, L et al. (1997) p53 mutation in squamous cell carcinomas from psoriasis patients treated with psoralen + UVA (PUVA). J Invest Dermatol 109:238-43
Nataraj, A J; Black, H S; Ananthaswamy, H N (1996) Signature p53 mutation at DNA cross-linking sites in 8-methoxypsoralen and ultraviolet A (PUVA)-induced murine skin cancers. Proc Natl Acad Sci U S A 93:7961-5